Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Basal Cell Nevus Syndrome 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IPI-926 × 1 year × Clear all
NCT06050122 2025-10-14

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Sol-Gel Technologies, Ltd.

Phase 3 Active not recruiting
140 enrolled
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡